PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX ( NBTX ) , a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today issued the following statement in response to recent media speculation concerning intentions for a potential public take-over.

Nanobiotix ( NBTX ) states that, to the best of its knowledge, there is no such intention to acquire control of the Company, and no process or assessment is being conducted toward that end. Additionally, the Company has identified factual inaccuracies in this media report which are not consistent with the Company’s most recent public disclosures.

About NANOBIOTIX ( NBTX )

Nanobiotix ( NBTX ) is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix ( NBTX ) is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix ( NBTX ) is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix ( NBTX ), visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Disclaimer

This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company’ management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on April 2, 2025 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2024 universal registration document filed with the AMF on April 2, 2025 under “chapter 1.5 Risk Factors”, and subsequent filings Nanobiotix ( NBTX ) makes with the SEC and AMF from time to time, including the Half-Year Report at June 30, 2025 filed on September 30, 2025 which are available on the SEC’s website at www.sec.gov and on the AMF's website at www.amf.org, The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix ( NBTX ) assumes no obligation to update these forward-looking statements publicly.

Communications Department

Brandon Owens

VP, Communications

+1 (617) 852-4835

[email protected] 

Attachment

2026-03-25 -- NBTX -- Statement Regarding Recent Media Rumor -- FINAL Image: https://www.globenewswire.com/newsroom/ti?nf=OTY3ODQxMyM3NTAzMjMzIzEwMTExNjI=

Image: https://ml.globenewswire.com/media/NGZmMjIyZTMtYmE1ZS00M2Y1LTgzYjUtNjFiZmMzMTg4ZmQ5LTEwMTExNjItMjAyNi0wMy0yNS1lbg==/tiny/Nanobiotix-S-A-.png Image: Primary Logo

Source: Nanobiotix S.A. ( NBTX )